

## PUBLIC HEALTH ALERT

Substance abuse treatment providers, clinicians, outreach workers, and public health clinics should be aware of the following information. Phenacetin is commonly used as an adulterant in illicit drug products, most often in cocaine exhibits, but has also been identified in samples containing heroin and/or fentanyl or multicomponent seized material products. The addition of phenacetin to illicit drugs may be due to it's minor euphoric effects, influence on some side-effects of cocaine due to its analgesic action, or to disguise the bitter taste of cocaine without compromising the physical properties of the product - both have similar melting points. Phenacetin is a known carcinogen and has associated adverse effects on cardiovascular, renal and urologic systems. Exposure to phenacetin is associated with nephrotoxicity, nephropathy, hemolytic anemia, methemoglobinemia, and kidney and bladder cancer.

**Background:** Phenacetin, a pain-relieving and fever-reducing drug, was discovered as an analgesic in 1887. It was one of the first synthetic fever reducers on the market and one of the first non-opioid analgesics without anti-inflammatory properties. Due to its hazardous side effects, including carcinogenic and kidney-damaging properties, the Food and Drug Administration (FDA) ordered its withdrawal from drug markets in 1983. Since being withdrawn phenacetin has become a common adulterant of illicit substances. In a 9-year longitudinal study of cocaine powders in the Netherlands, the percentage of samples containing phenacetin increased from 1.6 to 40.6 with a peak of 48% in 2006. Additionally, phenacetin was the most frequently identified adulterant in the samples.

#### Phenacetin

#### **Recommendations for Clinicians**

- Be aware that illicit drugs may contain toxic adulterants that can complicate the clinical presentation.
- Be familiar with the signs and symptoms associated with phenacetin toxicity.
- Be aware that routine hospital drug tests will not disclose the presence of phenacetin, which requires a special test.

#### <u>Frequent Indicators of Toxicity of</u> <u>Street Drugs Containing</u>

### <u>Phenacetin</u>

- Headache
- Nausea
- · Shortness of breath
- Cyanosis
- Ataxia
- Lethargy
- Confusion
- Hallucinations
- Methemoglobinemia

#### **Recommendations for MEs & Coroners**

 Conduct testing for phenacetin in suspected stimulant or opioid-related fatalities.

#### <u>Recommendations for Forensic and Clinical</u> <u>Laboratories</u>

- Include phenacetin in the scope of testing.
- Develop sensitive confirmatory procedures for common adulterating agents, including phenacetin.
- Consider laboratory analysis of seized drug samples taken from suspected drug overdose investigations.
- Share data on adulterants in drug seizures in your jurisdiction with local health departments, medical examiners and coroners.

#### Phenacetin Positivity in Seized Drug Testing in the US

• An ongoing project at the FRFF (2017-present), supported by the Colombo Plan and JMJ Technologies, is the analysis of seized drug exhibits for the presence of toxic adulterants. A summary of the phenacetin findings by state is shown below. Phenacetin was commonly identified in samples containing cocaine, but also in cases with heroin and/or fentanyl. Data collected from the same states over the four years of the project has found widespread use of phenacetin as an adulterant and a trend of increasing frequency of detection.

State	Phenacetin Positives	% Positivity
New Hampshire (n=200)	120	60.0%
California (n=174)	88	50.5%
Florida (n=200)	85	42.5%
Pennsylvania (n=357)	84	23.5%
Vermont (n=509)	116	22.7%
Maryland (n=32)	4	12.5%
Illinois (n=399)	48	12.0%
Ohio (n=190)	22	11.5%
Texas (n=600)	22	3.7%
Kentucky (n=398)	13	3.3%

#### Phenacetin Reported Internationally

• Countries reporting illicit drug products adulterated with phenacetin as part of the International Toxic Adulterants Database (ITAD) program and/or during The 2nd International Symposium of Forensic Drug Testing Lab Directors in Singapore.





**Health Impacts:** Concomitant use of phenacetin and illicit drugs can enhance the toxicity of the illicit drug. Phenacetin use has been associated with a higher likelihood of reported adverse effects in drug consumers, including cardiac arrythmias and hallucinations. Effects in the case of an overdose related to phenacetin consumption may include confusion, ataxia, lethargy, headache or methemoglobinemia. Chronic use of phenacetin is associated with nephrotoxicity leading to renal failure and back and flank pain. Intranasal administration may result increased toxicity due to a lack of CYP1A2 in the nasal mucosa, which is known to metabolize phenacetin *in vivo*. Phenacetin is metabolized to paracetamol (acetaminophen), which is also a pharmacologically active substance and detectable with laboratory testing.

In a study reviewing cocaine adulterants in blood samples (n=97), phenacetin was identified in 19% of the samples. Ante -mortem blood concentrations range from 14-166 ng/mL and 28-1151 ng/mL in post mortem samples. In a case resulting in death from the rupture of packages of cocaine containing phenacetin in a body packer, phenacetin blood concentrations reached 20,000 ng/mL, however, the cause of death was attributed to cocaine overdose. Phenacetin was quantitated in the packages at a concentration of 30% with cocaine quantitated at a concentration of 20%. Phenacetin is known to be redistributed after death.

Health providers should consider the possibility of exposure to phenacetin in patients who maybe experiencing cocaine toxicity and have cyanosis, methemoglobinemia, and/or chronic renal effects, which may be due to papillary necrosis and urothelial cancer.

#### **References and Related Articles:**

Brunt TM, Rigter S, Hoek J, Vogels N, van Dijk P, Nieskin, RJM (January 2009). "An analysis of cocaine powder in the Netherlands: Content and health hazards due to adulterants." Society for the Study of Addiction. 104 (5): 798-805. doi:10.1111/j.1360-0443.2009.02532.x.

Cole C, Jones L, McVeigh J, Kicman A. (April 2010). "CUT: A guide to adulterants, bulking agents and other contaminants found in illicit drug." Liverpool John Moores University. ISBN: 978-1-907441-48-6.

Dubach UC, Rosner B, Pfister E. (January 1983) "Epidemiological study of abuse of analgesics containing phencetin. Renal morbidity and mortality." New England Journal of Medicine 308 (7): 357-362. doi: 10.1056/NEJM198302173080703.

Dubach UC, Rosner B, Stürmer T. (January 1991) "An epidemiological study of abuse of analgesic drugs. Effects of phenacetin and salicylate on mortality and cardiovascular morbidity." New England Journal of Medicine 324 (3): 155-160. doi: 10.1056/ NEJM199101173240304.

Fiorentin TR, Krotulski AJ, Martin DM, Browne T, Tripplet J, Conti T, Logan BK. (May 2019). "Detection of cutting agents in drugpositive seized exhibits within the United States." Journal of Forensic Science 64 (3): 888-896. doi: 10.1111/1556-4029.13968.

Fucci N (April 2004). "Phenacetin and cocaine in a body packer." Forensic Science International. 141 (1): 59-61. doi.org/10.1016/ j.forsciint.2003.12.012.

Gameiro R, Costa S, Barroso M, Franco J, Fonseca S (June 2019). "Toxicological analysis of cocaine adulterants in blood samples." Forensic Science International. 299: 95-102. doi: 10.1016/j.forsciint.2019.03.005.

Jacobs HS. (May 1964). "Phenacetin Abused." British Medical Journal. 1 (5394): 1381. doi: 10.1136/bmj.1.5394.1381-b.

Mihatsch MJ and Knüsli. (November 1982). "Phenacetin Abuse and Malignant Tumors: An autopsy study covering 25 years (1953-1977)." Wiener klinische Wochenschrift. 60 (21): 1339-1349. doi: 10.1007/BF01716213.

Pawlik E, Mahler H, Hartung B, Plässer G. (April 2015). "Drug-related death: Adulterants from cocaine preparations in lung tissue and blood." Forensic Science International. 249: 294-303. doi: 10.1016/j.forsciint.2015.02.006.

Prescot LF. (October 1980) "Kinetics and Metabolism of Paracetamol and Phenacetin." British Journal of Clinical Pharmacology. 10 (suppl 2): 291S-298S. doi: 10.1111/j.1365-2125.1980.tb01812.x.

The 2nd International Symposium of Forensic Drug Testing Lab Directors, Singapore July 22-25, 2019. Organized by the Colombo Plan Secretariat on behalf of the Bureau of International Narcotics and Law Enforcement Affairs (INL) and United States Department of State, reported January 9, 2020.

Acknowledgements: This report was prepared by Amanda L.A. Mohr, MS; Thom Browne, MA; Lewis Nelson MD, and Barry K. Logan, PhD. Funding for this document was received by the Fredric Rieders Family Foundation from the Colombo Plan via U.S. Department of State/INL under 2019-RG-061 and 2017-RG-61, and other Colombo Plan funding sources.

The opinions, findings, recommendations, and conclusions expressed in this publication are those of the authors and do not necessarily reflect those of the U.S. Department of State. More information on phenacetin is available by contacting <u>mandi.mohr@frfroundation.org</u>.

1.

2.

3. 4.





# Phenacetin Adulterated Drug Exposure – Diagnosis and Treatment

		+	
	Signs & Symptoms of I	ntoxicat	ion/Chronic Use
	Physical		Behavioral
	Cyanosis Flushed face Headache	attrib co-ing Phena	vioral effects are likely outed to illicit substance gested with phenacetin. acetin-related behavioral ts are rare
		Ļ	
	Provider	Respons	se
	Physical		Behavioral
	Measure methemoglobin if cyano Measure electrolytes and renal fu Measure CBC with differential Check apap level of LFTs Administer IV fluids Correct abnormalities in lab findin CBC and electrolytes Administer sodium bicarbonate if is acidotic Consider administering oral activa charcoal if phenacetin is ingest	nction ngs on patient ated	No treatment
	FURTHER TREA		
	Once patient's behavior and physic further treat	al respons	ses are stable, then deterr
	÷		
	YES		NO
symptomatic medical toxic contraindicat deficiency is Mediterrane Recheck met until normali Correct acido	logbin >20% or if patient is even if <20%, call the poison center or cologist. Note: Phenacetin is ted in patients with G6PD. Severe G6PD more common in SE Asia and an populations. hemoglobin concentrations every 2-4 h zing osis with sodium bicarbonate V saline solutions		In most cases, further tre